United States Últimas notícias

On this episode of Stock Movers: - CoreWeave (CRWV) share are higher in premarket trading as Goldman Sachs upgrades the cloud-computing provider to buy from neutral, a move that comes in the wake of heavy volatility related to concerns over the company's debt. - Cleveland-Cliffs (CLIF) shares jumped after it reported third-quarter profit that topped analysts' estimates as steel prices rose and Trump administration tariffs eroded US imports. - Intel (INTC) is gaining in the premarket as JPMorgan upgrades to neutral from underweight, noting that the chipmaker's turnaround might take years, but the management's execution has been solid.

Veradermics (NYSE:MANE) reported positive Phase 3 results for VDPHL01, with both dosing regimens significantly increasing hair counts versus placebo after six months.

Cosmos Health (NASDAQ:COSM) forecasts approximately $15 million in fourth-quarter 2026 U.S. direct-to-consumer revenue, with projected gross profit of $10.5 million.

The forecast represents a 70% gross margin for its U.S. online business, compared with roughly 8% company-wide GAAP gross margin in Q2.

Anthropic PBC says it plans on depositing 5% of its shares in a new fund for "the public good." The money could be used to offset AI's impact on the job market. The artificial intelligence startup is preparing for what could be one of the biggest IPOs ever. Bloomberg's Ed Ludlow reports.

VinFast (NASDAQ:VFS) reported second-quarter 2026 revenue of $1.20 billion, up 85.5% year over year, supported by higher electric vehicle deliveries.

JPMorgan Chase & Co. deployed $230 billion of capital, providing equity and debt financing across a handful of areas, including energy independence and defense and aerospace, in the first year of its decade-long effort to plow $1.5 trillion into industries that bolster US economic security. Herman Chan of Bloomberg Intelligence has more on Bloomberg Television.

Peoples Bancorp of North Carolina (NASDAQ:PEBK) reported third-quarter 2026 net earnings of $5.7 million, up approximately 54% from $3.7 million a year earlier.

Alpha Tau Medical (NASDAQ:DRTS) received FDA authorization to expand its REGAIN brain cancer trial from 10 to 20 patients across three U.S. centers.

Peter Tchir, head of macro strategy at Academy Securities, says he is "nervous" about a potential selloff of artificial intelligence-related debt as he sees "faux liquidity" in markets. He speaks on "Bloomberg Surveillance."

Eos Energy Enterprises (NASDAQ:EOSE) expects preliminary third-quarter 2026 revenue of US$82–US$83 million, representing 169%–172% growth from the prior year.

TCGX Acquisition Corp. (NASDAQ:TCGX) agreed to merge with TriGemX Bio in a transaction expected to generate approximately $246 million in gross proceeds.

Johnson & Johnson (NYSE:JNJ) reported 35% combined fistula remission at Week 48 with TREMFYA in its Phase 3 FUZION Crohn's disease trial.